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1. Introduction
Heart failure (HF) after myocardial infarction (MI) or the ischemic myocardiopathy (ICM)
continues to be the most prevalent cause of morbidity and mortality worldwide. MI results in
myocardial necrosis, scar formation, ventricular remodeling and eventually HF or death. Faced
with the end stage of ICM, the most of present therapy protocols could only slow worsening
of HF. Cardiac resynchronization therapy may be definite therapeutic effect to those cases with
HF and complete left bundle-branch block. Heart transplantation can more efficiently improve
the cardiac status, but, limited donor supply and organ rejection confine its widespread use.
As a result, a significant proportion of survivors with ICM will still develop HF and have
briefer life-span. Pathologically, HF and myocardial remodeling aggratate each other and a
core pathogenic factor of ICM is loss of massive cardiomyocytes [1]. In fact, the myocardium
itself posseses little capacity for self-regeneration. Although there are still considerable dispute
in the clinical therapeutic effect based on stem cells (SCs), the positive results obtaned in the
repair of damaged myocardium indicated it has become a promising strategy [2-4]. In this
regard, an array of SCs types has been identified and applied, including bon marrow-derived
mononuclear cell (BM-MNCs) [5] and umbilical cord blood-derived stem cells(UCB-SCs). At
the current state of SCs clinical application there is no convincing data showing the superiority
of any tissue committed monopotent stem cells (TCSCs), so heterogenous population of BM-
MNCs is most often used [6]. Some recent studies have showed pluripotent stem cells (PSCs)
are precursors of TCSCs during organ/tissue rejuvenation and a source of these cells in
emergency situations when organs are damaged (e.g., MI or stroke). The application of PSCs
has showed very encouraging results. PSCs includes induced pluripotent stem cells (iPSCs)
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using gene transfer [7-8] and very small embryonic-like embryonic/epiblast-like stem cells
(VSELs) isolated from the adult tissues or UCB [9]. A rare Sca1+Lin−CD45− SCs population
were initially identified, isolated and named as VSELs in adult mice using fluorescence
activated cell sorting (FACS) [10]. Although VSELs are currently studied in a lot of laboratories
worldwide, the research series of VSELs was mainly contributed by Kucia & Ratajczak and
their colleagues. VSELs possess very primitive morphology and express PSCs markers (e.g.,
Oct4, Nanog, and SSEA-4) as well as the surface phenotype Sca1+/ CD133+Lin−CD45− in mice /
humans. As VSELs can be mobilizated into PB following acute MI [11], improve heart function
and alleviate cardiac remodeling[12,13], these cells seem to possibly become an optimal seed
cells for cardiovascular repair. Recently, employing anti-CD133-conjugated paramagnetic
beads followed by staining with Aldefluor has also been proposed for a faster large-scale
VSELs isolation [14]. More recent evidences demonstrate that VSELs deposited in adults tissue
share several markers with epiblast/germ line cells and play a role in rejuvenation of the TCSCs
responsible for tissue regeneration/repair after organ injuries. Even, VSELs with maximum
regenerative potential are recommended as the true PSCs in adult tissues, whereas the
hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are actually progenitor
SCs arised from asymmetric cell division of VSELs [15]. As a promising candidate, their unique
characteristics and potentiality may have very important pathophysiological and therapeutic
implications for regenerative medicine including myocardial and endothelial repair.
2. Discovered history of VSELs
Small cells able to differentiate into cells from all three germ layers and called “spore-like stem
cells” were isolated from adult mammalian tissues, however, it was not provided for these
small SCs how to be purified and for their surface markers how to be expressed in the original
paper [16]. Afterwords, small SCs expressing CXC chemokine receptor 4 (CXCR4+) and
markers characteristic for embryonic stem cells (ESCs), epiblast stem cells (EPSCs), and
primordial stem cells (PGCs) were purified from the murine BM and several adult organs.
Based on their small size, presence of PSCs markers, distinct morphology (open-type chro‐
matin, large nucleus, narrow rim of cytoplasm with multiple mitochondria) and ability to
differentiate into all three germ layers, including mesoderm-derived cardiomyocytes, these
cells were named as VSELs [9].
3. Found source of VSELs
The rare Sca-1+Lin−CD45−SCs population was initially discovered in mice BM 9. Phenotypi‐
cally similar cells were subsequently identified and purified in murine peripheral blood (PB),
fetal liver, brain, retina, kidneys, pancreas, skeletal muscles spleen, and thymus[17]. In
humans, VSELs were identified in UCB, PB, BM, and cardiac tissue[18]. VSELs deposited in
adult tissues seem to be a reserve pool for TCSCs [19].
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4. Morphology of VSELs
The most common shape feature of VSELs is that they possess very primitive morphology and
relatively small size. The distinctive morphology of VSELs was confirmed using confocal and
transmission electron microscopy [9,10]. Comparison with other populations of cells, murine
VSELs (4-6 µm) are smaller than HSCs, MNCs and granulocytes and erythrocytes, but, larger
than platelets. Human VSELs (6–8 µm) are larger than murine. At the ultramicrostructural
level, they show a very immature morphology, for example, possess a relatively large nucleus
surrounded by a narrow rim of cytoplasm, a few mitochondria, scattered ribosomes, small
profiles of endoplasmatic reticulum and a few vesicles [20].Recently, the high resolution of
ImageStream system (ISS) analysis enables the identification of objects as small as 1 µm in
diameter. Employing ISS analysis, murine VSELs are more precisely confirmed as ~3.6 µm in
diameter [21].
5. Molecular biology and functional features of VSELs
VSELs not only possess the primitive morphology of early developmental cells but also express
typical markers for PSCs
Characteristic  markers  of  VSELs  were  confirmed using  several  complementary  research
tools including flow cytometry (FCM), ISS,  direct  immunofluorescence staining, confocal
microscopy, reverse-transcription polymerase chain reaction (RT-PCR) and etc. Early em‐
bryonic  markers  (Oct-4,  Nanog,  SSEA-1,  Rex1,  Dppa3,  Rif-1)  were  demonstrated  at  the
protein  /mRNA  levels  using  immunofluorescent  staining,  ISS  and  FACS  [21,22].  VSELs
express SSEA-1 antigen on their surface and Oct-4 in their nuclei. Recent study indicates
that  the  promoters  of  Oct4  and  Nanog  contain  transcriptionally  active  chromatin  in
VSELs excluding the possibility of amplification of pseudogenes [23]. CD133+Lin−CD45−
VSELs  identified  in  Human UCB like  their  murine  counterparts,  i)  highly  express  telo‐
merase,  ii)  are  diploid,  and iii)  are  viable,  as  shown by their  ability  to  exclude dye (7-
aminoactinomycin D). Moreover, some of the CD133+Lin−CD45− VSELs, which represent
only a very small subfraction among UCB Lin−CD45−non-hematopoietic cells, may co-ex‐
press  other  stem cell  markers,  including CD34,  CXCR4,  and SSEA-4,  may contain other
stem  cell  types,  including  endothelial  progenitor  cells  (EPCs)  and  mesenchymal  stem
cells  (MSCs),  and may be identified based on very small  size (FSClow/SSClow) and co-
expression of CD133, CD34, and, CXCR4 [23].
Also, there are some differences of the VSELs phenotype between mice and humans. Human
VSELs surface markers consist of lin−CD45−CXCR4+, CD133+ and CD34− as confirmed on the
mRNA level by RQ-PCR and protein level by IF and ISS, whereas Murine VSELs express Sca-1
antigen [24].
VSELs express  chemokine receptor  CXCR4 and are  absent  of  pan-hematopoietic  marker
(CD45−) and hematopoietic lineage markers (Lin−) [9,10,25].  Further study demonstrated
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that VSELs can not primarily reveal hematopoietic ability immediately from isolation and
expansion, but may eventually acquire hematopoietic potential following co-culture in hem‐
atopoiesis permissive environment over OP9 stroma feeder layer and reconstitute hemato‐
poiesis in lethally irradiated mice 4–6 weeks after transplantation [26].
Freshly sorted VSELs can be expanded in coculture with C2C12 murine myoblast feeder lay‐
er. After 7 days of co-culture, approximately 5–10% of all VSELs form sphere-like clusters
consisting  of  a  few  hundred  cells  resembling  embryoid  bodies  (VSEL-derived  spheres,
VSEL-DSs). VSEL-DSs express placenta-like alkaline phosphatase. Expanded population of
VSELs isolated from VSEL-DS retain the pluripotent capacity and have ability to differenti‐
ate  into all  three germ layers,  including mesodermal cardiomyocytes,  ectodermal neural
cells and endodermal pancreatic cells [27].
The differentiation potency was also documented in circulating murine VSELs after injec‐
tion of G-CSF. Rapidly mobilized VSELs showed up-regulation of PSC markers. These find‐
ings  support  not  only  the  pluripotency  of  VSELs,  but  also  their  tissue  repair
function[10].Study  also  showed that  VSELs  possess  diploid  DNA.  They  do  not  express
MHC-1  and  human  leukocyte  antigen-D  related  (HLA-DR)  antigens  and  are  CD90−
CD105−CD29−.Moreover, if plated over a C2C12 murine sarcoma cell feeder layer, ~5–10%
of  purified  VSELs  are  able  to  form spheres  that  resemble  embryoid  bodies  [9].  Similar
spheres were also formed by VSELs isolated from murine fetal liver, spleen, and thymus
[17].  Interestingly,  VSELs  are  somewhat  heterogenous  developmentally.  Although all  of
VSELs express the Oct-4, some of them express genes that are more closely related to genes
expressed by EP-SCs and others to genes expressed by migrating PGCs [28].
In parallel, VSELs exhibits their potential biologic function. Oct-4+ SSEA-4+ SCs harvested
from BM via elutriation, has been recently shown to give rise into functional insulin-produc‐
ing cells in vivo in induced diabetic mice [29].In another report, VSELs purified from rat BM
successfully repaired damaged myocardium in a model of MI [30].
Similarly, in vivo exposure to hypoxia in mice elicits chemoattractant a gradients that pro‐
mote the mobilization of pluripotent very small embryonic-like stem cells from the bone
marrow to peripheral blood. VSELs in the BM are the primary source of lung epithelial cells
[31-33]. VSELs were also identified in neonatal retina and involved in optic nerve retinal re‐
generation in a rodent model [34]. VSELs may also play a major role as populations of cells
that preferentially give rise to induced pluripotent stem cells (iPSCs) when BM-derived stro‐
mal cells are induced to pluripotency by genetic manipulation [35].In particular, VSELs de‐
rived by parthenogenesis have also been identified successfully [36].
6. Isolation strategies of VSELs
Isolation of VSLEs using FACS is dependent on gating strategy based on their small size,
expression  of  PSC  (Oct4,  Nanog,  and  SSEA-4),  surface  markers  (CXCR4,  CD133  /Sca-1,
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CD34) and absence of hematopoietic lineage markers (lin, CD45). Briefly, the first step is
the lysis of red blood cells to obtain the fraction of nucleated cells. Erythrocyte lysis buf‐
fer is used instead of Ficoll centrifugation because the latter might deplete the population
of very small cells [14]. Subsequently, cells are stained and sorted with antibodies against
Sca-1 (murine VSELs) or CD133 (human VSELs), pan-hematopoietic antigen (CD45), hem‐
atopoietic lineages markers (lin), and CXCR4 [9]. Extended lymphocyte gate was used to
include events with diameter 2–10 µm, approximately consisting of VSELs. The width of
the gate was validated by using synthetic beads of predefined size (1–15 µm) [14]. Sever‐
al  other  approaches  to  define  the  population  of  small  cells  were  used,  including  ISS.
Above standard procedure employing FACS, however, is time consuming, which usually
requires up to 4 days to process and isolate VSELs from UCB MNCs in one entire cord
blood unit (~50–100 ml).  It  is not very difficult for the future clinical application to take
into consideration cell  viability,  the time of sorter usage, and the time commitment of a
sorter operator.
In order to speed up isolation of  VSELs,  a  faster large-scale isolation protocol  based on
anti-CD133-conjugated paramagnetic beads followed by staining with Aldefluor were re‐
cently employed. In this novel approach (i) A UCB research unit is lysed in a hypotonic
ammonium chloride solution for 15 min at room temperature to deplete erythrocytes and
washed twice in phosphate-buffered saline (1st step); (ii) A single-cell suspension of total
nucleated  cells  was  treated  with  antibodies  against  CD133  antigen-coated  immunomag‐
netic  beads and separated by a MACS Separator to obtan CD133+including VSELs (2nd
step);  and subsequently (iii)  The CD133(+)cell  fraction was reacted with the Aldefluor™
Kit  reagent  for  detecting  aldehyde  dehydrogenase  (ALDH).  Cells  were  incubated  with
phycoerythrin  (PE)-conjugated  murine  anti-human CD235a,  PE-CY7-CD45,  and  allophy‐
cocyanin (APC)-conjugated CD133/2.  Cells  were washed and resuspended in cold Alde‐
fluor  buffer  and  sorted  by  FACS  to  obtain  populations  enriched  in  CD45−GlyA
−CD133+ALDHlow  VSELs.The whole isolation process takes approximately 2-3 h per UCB
unit  and  these  small  Lin-CD45-CD133+cells  isolated  from  human  UCB  highly  express
Oct-4, Nanog, and SSEA-4 at both the mRNA and protein levels [13,14].
This new isolation protocol was based on the following rationale.(i) Using erythrocytes lysis
buffer was higher yield of VSELs than a Ficoll-Paque gradient centrifugation to remove
erythrocytes [14]. (ii) On the other hand, CD133+ VSELs are highly enriched for PSC tran‐
scription factor expression (e.g., Oct-4 and SSEA-4) [14]. (iii)Small erythroblast GlyA+ that are
present in UCB do not express CD45 antigen. Thus, selection for CD45−cells was used to enrich
for these cells.
The isolation from one entire UCB unit can obtan ~103/100 ml of UCB for CD45−GlyA
−CD133+ALDHlow cells and ~4×103/100 ml of UCB for CD45−GlyA−CD133+ALDHhigh cells.
Freshly isolated CD45-GlyA-CD133+ALDHhigh VSELs express more hematopoietic transcripts
(e.g., c-myb), CD45-GlyA-CD133+ALDH low VSELs exhibit higher levels of PSCs markers (e.g.,
Oct-4) [34,35].
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7. Special potency and hypothesized role of VSELs
PSCs must correspond to certain in vitro and in vivo conditions. According to these crite‐
ria,  PSCs should be provided with (i)  giving rise to cells from all  three germ layers,  (ii)
completing blastocyst development, and (iii) forming teratomas after inoculation into ex‐
perimental animals. ESCs are generally known as PSCs. However, both VSELs and iPSCs
are not different from ESCs in next two conditions. In special, There are some own unique
superiority that VSELs deposited in various adult organs as a backup for primitive stem
cells share several markers with epiblast/germ line cells, plays a role in rejuvenation of the
pool of TCSCs involved in tissue regeneration, but, not complete blastocyst development
and not form teratomas. During steady-state conditions, VSELs may be responsible for tis‐
sue rejuvenation and for processes of regeneration/repair after organ injuries. VSELs simi‐
larly as epiblast-derived PGCs change the epigenetic signature of some of the imprinted
genes and therefore remain quiescent in adult tissues. This quiescence of VSELs is epige‐
netically regulated by DNA methylation of genomic imprinting [36].VSELs highly express
growth-repressive genes (H19, p57KIP2, Igf2R) and downregulate growth-promoting ones
(Igf2, Rasgrf1). The unique genomic imprinting pattern may explain the quiescent status of
VSELs.  Thus,  VSELs may be progeny of epiblast  cells  to develope tissues and a reserve
pool  of  PSCs to  repair  tissue.  Furthermore,  the  quiescent  state  of  VSELs may also be  a
physiological protective mechanism of preventing uncontrolled proliferation, tumor forma‐
tion [28]. Furthermore, The bone-forming activity of VSELs, exceeded the activity of other
populations of BM-purified cells tested in the same assay if embedded in gelatin sponges
and implanted into living mice. Even, as few as 500 UCB VSELs was capable of forming
bone-like structures in vivo [37]. Based on these finding, VSELs have been described as at
the top of the hierarchy for the mesenchymal and endothelial lineages in BM [38,39]. Inter‐
estingly, the content of VSELs from mice BM at different ages (2 months-3 years) was eval‐
uated  employing  FCM.  the  number  of  these  cells  gradually  decreases  over  time  from
0.052±0.018% to 0.003±0.002% between age of 2-months and 3-years, respectively. In anoth‐
er report, the concentration of VSELs is much higher in BM of long-lived (e.g., C57Bl6) as
compared to  short-lived  (DBA/2J)  mice.  Especially,  not  only  a  number  of  these  cells  in
adult organs decreases with the age but also their ability to form spheres containing VSEL-
DS declaims with time. Whereas, a number of monopotent hemato/lymphopoiesis commit‐
ted HSC increase in older animals [40,41].This age-dependent content and ability of VSELs
in adult organs may explain that these cells could play a pivotal role in the normal cell
turn over and the life span control of mammals.Moreover, a significantly higher number
of VSELs in long-living murine strains (e.g., Laron dwarfs and Ames dwarfs), whose lon‐
gevity is explained by low levels of circulating IGF1 and a decrease in IIS. By contrast, the
number of VSELs is reduced in mice with high levels of circulating IGF1 and enhanced IIS
(e.g., growth hormone-overexpressing transgenic mice) compared to normally aging litter‐
mates [42,43]. There was a envision that in future, VSELs could be isolated from the pa‐
tient  at  young  age  and  than  inject  back  into  same  recipients  several  years  latter  to
regenerate damaged organs and to expand life-span, in case of major health complications
(e.g., heart infarct, stroke) due to aging.
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8. Mobilization and cardiovascular repair of VSELs
VSELs express early cardiac and endothelial lineages markers (GATA-4, Nkx2.5/Csx, VE-
cadherin, and von Willebrand factor), SDF-1 chemokine receptor CXCR4. Under steady-state
conditions, VSELs circulate in PB is very rare, however, undergo rapid mobilization during
acute MI [44].The processes are regulated by SDF-1, and its receptor CXCR4 as well as other
important cytokine-receptor systems of regulating the stem cell mobilization and homing
include leukemia inhibitory factor (LIF) – LIF receptor, hepatocyte growth factor (HGF) – c-
met axis, stem cell factor-CD117 axes [45-48]. Interestingly, the number of these cells in PB is
significantly higher in younger acute MI patients than in older ones. Number of VSELs was
also correlated with left ventricular ejection fraction, troponin I and creatinine kinase-MB levels
[44]. Further studies provided evidence that VSELs can be mobilized into PB in adult patients
injected with granulocyte-colony stimulating factor (G-CSF) and their number could be of
prognostic value [49].Consistently, a protocol which VSELs differentiate into cardiomyocytes
in vitro has been developed. In the first step, VSELs are co-cultured with myoblast line (C2C12)
where the cells expand and form VSEL-DS.Subsequently, VSELs isolated from VSEL-DS by
FACS sorting are plated on cardiac media to differentiate them into cardiomyocytes. The
period over 21 days in expression of early cardiac markers and cardiac structural proteins also
resembles the maturation of cardimyocytes from ESCs [50].
Murin experiments in vivo also showed that expanded and subsequent cardiopoiesis-guided
VSELs were markedly more effective than expanded and non-pre-differentiated cells. Inter‐
estingly, beneficial effects were observed despite use of only small number (104 cells) of VSELs.
At the same time a much higher number of hematopoietic cells (105 cells) was not effective [37].
so far, a cochrane controlled trial called Myocardial Regeneration by Intracoronary Infusion
of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) study are
available.The objective study was to assess the efficacy of intracoronary infusion of autologous
BM-derived CD34+CXCR4+ progenitor cells in comparison to non-selected BMMNC on LVEF
in patients with acute ST-segment elevation MI and reduced below 40% LVEF. CD34+CXCR4+
cells which is enriched for VSELs were isolated by two step immunomagnetic selection using
the magnetic beads. The reslut demonstrated that the use of selected CD34+CXCR4+ cells or
non-selected BMMNCs in patients with significantly reduced LV function is safe, feasible and
not leads to a significant improvement of LVEF, there was however a trend in favour of cell
therapy. In another, athough CD34+CXCR4+ cells were not pure population of VSELs, The use
of a relatively small number of selected CD34+CXCR4+ cells is associated with similar trend
as the use of 100 times higher number of non-selected BMMNCs (1.90 × 106 vs. 1.78 × 108) for
improvement of LVEF. It also further showed which the activity of VSELs is more superior
than that of BMMNC [52].Based on above finding, administration of VSELs after an acute MI
increases LVEF and improves left ventricular structure, and these benefits remain stable during
long-term follow-up. Although the mechanisms remain under investigation, paracrine effects,
regeneration of cellular constituents, and stimulation of endogenous stem/progenitors may
play combinatorial roles [49], because the rare VSEL-derived cardiac myocytes expressing
cardiac markers were present in the recipients myocardium [50,52].
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Thus, VSELs may serve as an ideal SCs source for cardiac repair by their ability to secrete
various cardioprotective growth factors/cytokines, as well as their ability to differentiate into
cardiomyocytes and endothelial cells
9. Remaining challenges of VSELs application
However, there are also some challenges and conflict coming out from recent VSELs’ stud‐
ies.At first, a recent study showed that VSELs from human UCB lack SCs characteristics and
fail to expand in vitro under a wide range of culture conditions [53].We also found that it is
very difficulte for human VSELs to be cultured or expanded in vitro using general culture
conditions. Thus, it has to be further determined whether these cells are merely developmental
remnants found in the adult tissue that cannot be harnessed effectively for regeneration or
whether they are real SCs population for regeneration medicine.
Subsquently, the biological characteristics and role of VSELs were studied mostly in mice and
human. No information of VSELs from large animal close to human has been reported. Future
clinical studies using autologous VSELs are needed to validate those promising large animal
experimental data.
Furthermore, it has seldomly obtained for parallel experiments to compare several populations
of putative SCs to determine the similarities and differences between these cell populations.
10. Summary
Overall, as mentioned above, the importance of SSEA-1+Oct-4+Sca-1+/ CD133+CXCR4+Lin
−CD45− pluripotent VSELs in adult tissue or UCB is now being stressed. New data from Kucia
& Ratajczak group and other groups has provided mounting evidence on the existence and
potential biological role of VSELs mostly in mice. VSELs would very possibly be a promising
PSCs population for cardiac repair in future clinical application of patients with ICM. Their
cardiogenic potential should be confirmed in large animal similar to humans and technical
issues regarding their isolation, expansion and differentiation need to further be addressed.We
also look forward to share how to higher efficiently isolate and expand these rare cells as well
as to know about further information on their biology and in vitro and in vivo differentiation
potential.
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